{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig2ynnp7nxjvi3ex2zkkvavrpqwdikfjwya2cxp3k5lpqaqclc33m",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3me7o6p7b7pn2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidwyxdz4sr7xaeumklcmpcwrwxzgvqei2b54z3xpovj2a45we3mem"
    },
    "mimeType": "image/webp",
    "size": 68402
  },
  "path": "/releases/2026/02/260206012229.htm",
  "publishedAt": "2026-02-06T11:03:34.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "Colorectal cancer has long baffled scientists because, unlike most tumors, patients often do better when their cancers are packed with immune-suppressing regulatory T cells. New research finally explains why. Scientists discovered that these T cells aren’t all the same: one subtype actually helps keep tumors in check, while another shields cancer from immune attack. The balance between these “good” and “bad” cells can determine whether a tumor grows or shrinks.",
  "title": "Why colorectal cancer breaks the immune system’s rules"
}